Volume 10 Issue 2, April 2016

MyCartis’s Evalution platform provides multiplex detection of biomarkers ideal for research and analysis.

Repertoire Genesis is revealing new possibilities for personalized diagnosis and treatment with its technology platform for unbiased next-generation T and B cell receptor repertoire analysis.

The Antibody Lab is focused on improving screening for preeclampsia during pregnancy and is seeking strategic partners to change the current risk-assessment paradigm.

Coyote Biosciences has developed a range of miniaturized, portable and battery-powered molecular diagnostics instruments that provide point-of-care testing solutions—from detecting infectious diseases to profiling cancer—for health care providers and patients globally.

Kaytee Bio is focusing on mechanisms to identify diagnostics and treatments for rheumatoid arthritis.

VolitionRx, a life sciences company, has developed an array of simple blood tests to improve the detection of a wide range of cancers at early stages, with the goal of dramatically improving survival rates in patients.

The drive to enhance biologic therapies through more convenient delivery methods is creating dealmaking opportunities for companies with innovative delivery technologies.

Eos Biosciences has developed the Eosome, a versatile drug delivery platform that maximizes efficacy through efficient intracellular delivery of therapeutic payloads. Eosomes can be adapted for many disease indications and for the delivery of a wide variety of drug modalities.

Google Ventures-backed Rani Therapeutics has developed a swallowable pill that injects biologic drugs directly into the intestine without degrading the drug in the stomach or gastrointestinal tract.

Highland Therapeutics’ novel drug delivery platform is designed to offer control over the timing of drug release and the duration of therapeutic exposure, enabling dosing at night for treatment effect starting the moment the patient wakes and lasting throughout the day.

Portal Instruments’ needle-free and digitally controlled jet-injection device affords less injection-related pain and seamless integration with digital health care platforms, which could help improve patient tolerability and compliance.

stat-MD™ Global Health Management,Information, and Surveillance System

After a slow arrival, digital advances in health care are now progressing rapidly. Boosted by a $4.5 billion investment in 2015, the digital health market is now seeing the development of a wave of wearable and mobile technologies to monitor, control and collect data on many of today’s diseases.